Pulmatrix, Inc. (PULM): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the story behind Pulmatrix, Inc. (PULM), and how this biopharmaceutical company operates? With a recent market cap of $19.7 million as of April 11, 2025, and a stock price of $5.40, Pulmatrix has been making headlines. Keep reading to discover Pulmatrix's journey, its innovative iSPERSE™ technology, its mission to tackle unmet medical needs, and how it navigates the financial landscape to drive growth and innovation in the pharmaceutical industry.

Pulmatrix, Inc. (PULM) History

Company's Founding Timeline

Year established

The company was established in 2003.

Original location

The company was originally located in Cambridge, MA.

Founding team members

The founding team included Dr. Robert Langer, Dr. Daniel Kohane, and Dr. Ulrich стиа.

Initial capital/funding

The initial funding was a $6.5 million Series A round led by Polaris Partners in 2004.

Company's Evolution Milestones

Company's Transformative Moments

• Reverse Merger (2014): The reverse merger with Explorer Petroleum Corporation marked a significant turning point, enabling the company to become publicly traded and access public capital markets. This move provided the financial resources needed to advance its clinical programs.
• iSPERSE™ Technology Development: The development and refinement of the iSPERSE™ (inhaled Spherical Powder for Enhanced Respirability) technology has been central to the company's strategy. This platform enables the delivery of various drugs directly to the lungs, enhancing their efficacy and reducing systemic side effects.
• Focus on ABPA: A key transformative decision was to focus on Pulmazole for ABPA in asthma patients. This strategic focus allowed the company to concentrate its resources on a specific indication with a clear unmet medical need, potentially accelerating its path to regulatory approval and commercialization.
• Collaboration with Pharmaceutical Companies: Collaborations, such as the one with Janssen Pharmaceuticals, have been pivotal in validating the company's technology and providing additional funding and expertise. These partnerships help expand the application of iSPERSE™ technology and support further research and development efforts.

To gain more insights into the company's goals, refer to this link: Mission Statement, Vision, & Core Values of Pulmatrix, Inc. (PULM).

Pulmatrix, Inc. (PULM) Ownership Structure

Pulmatrix, Inc. operates with a mixed ownership structure, including a combination of institutional, retail, and insider holdings that influence its governance and strategic direction.

Pulmatrix, Inc.'s Current Status

Pulmatrix, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol PULM. This status allows it to raise capital through the issuance of stock and requires it to adhere to regulations set forth by the Securities and Exchange Commission (SEC), ensuring transparency and accountability to its shareholders.

Pulmatrix, Inc.'s Ownership Breakdown

The ownership of Pulmatrix, Inc. is distributed among various types of shareholders, each holding a certain percentage of the company's outstanding shares. The following table summarizes the ownership breakdown:

Pulmatrix, Inc.'s Leadership

Pulmatrix, Inc.'s direction is guided by a team of experienced leaders. Key figures include:

• Robert W. Clarke: Chief Executive Officer
• David Michael Solack: Chief Financial Officer
• Theodore T. Daley: Director

To gain further insights into the company's goals, check out: Mission Statement, Vision, & Core Values of Pulmatrix, Inc. (PULM).

Pulmatrix, Inc. (PULM) Mission and Values

Pulmatrix, Inc. focuses on developing innovative inhaled therapies to address serious pulmonary and other diseases. The company's mission is rooted in improving patient lives through novel drug delivery technologies.

Pulmatrix, Inc.'s Core Purpose

Official mission statement

Pulmatrix, Inc.'s mission statement is: 'To improve the lives of patients with serious pulmonary and other diseases by advancing innovative inhaled therapies based on our proprietary iSPERSE™ technology.'

• Pulmatrix aims to transform respiratory care by creating effective inhaled therapies.
• The company is dedicated to addressing unmet needs in pulmonary medicine.
• Pulmatrix leverages its iSPERSE™ technology to develop novel drug formulations.

Vision statement

Pulmatrix, Inc.'s vision is to be a leader in inhaled drug delivery, recognized for its innovative technologies and commitment to patient well-being.

• Pulmatrix strives to be at the forefront of inhaled drug delivery advancements.
• The company envisions a future where its therapies significantly improve patient outcomes.
• Pulmatrix is dedicated to expanding its pipeline of inhaled products.

Company slogan/tagline

Pulmatrix, Inc. does not have a prominently publicized official slogan or tagline. However, their focus on innovation and improving patient lives can be seen as an implicit tagline.

• While not a formal tagline, 'Innovating Inhaled Therapies' encapsulates their core activity.
• Their commitment to patient well-being is a recurring theme in their communications.

For more in-depth information, you can visit: Mission Statement, Vision, & Core Values of Pulmatrix, Inc. (PULM).

Pulmatrix, Inc. (PULM) How It Works

Pulmatrix, Inc. operates as a clinical-stage biopharmaceutical company focused on developing inhaled therapies to prevent and treat respiratory diseases using its proprietary iSPERSE technology.

Pulmatrix, Inc.'s Product/Service Portfolio

Pulmatrix, Inc.'s Operational Framework

Pulmatrix operates primarily as a research and development company, focusing on advancing its pipeline of inhaled drug candidates through preclinical and clinical studies. Their operational framework includes:

• Drug Development: Utilizing the iSPERSE technology platform to formulate and develop inhaled therapies.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
• Partnerships: Seeking strategic partnerships for further development and commercialization of their products.
• Manufacturing: Working with contract manufacturing organizations (CMOs) to produce clinical trial material.

The company generates value by identifying unmet needs in respiratory diseases, developing innovative inhaled therapies, and seeking regulatory approval for these therapies. Successful commercialization, either independently or through partnerships, is essential for generating revenue.

Pulmatrix, Inc.'s Strategic Advantages

Pulmatrix's strategic advantages stem from its proprietary iSPERSE technology and its focus on inhaled therapies for respiratory diseases:

• iSPERSE Technology: This platform enables the development of dry powder formulations with unique properties, such as controlled particle size and improved drug delivery to the lungs.
• Targeted Drug Delivery: Inhaled therapies allow for direct delivery of drugs to the lungs, potentially improving efficacy and reducing systemic side effects.
• Focus on Unmet Needs: Pulmatrix is targeting respiratory diseases with significant unmet needs, such as invasive pulmonary aspergillosis and asthma, which provides opportunities for market differentiation.
• Experienced Management Team: A team with experience in drug development, regulatory affairs, and commercialization.

To gain more insights into the company's goals, check: Mission Statement, Vision, & Core Values of Pulmatrix, Inc. (PULM).

Pulmatrix, Inc. (PULM) How It Makes Money

Pulmatrix, Inc. primarily operates as a clinical-stage biopharmaceutical company, focusing on developing inhaled therapies to prevent and treat respiratory diseases. Its revenue generation is currently centered around securing research and development collaborations, grants, and, potentially in the future, product sales upon regulatory approval of its drug candidates.

Pulmatrix, Inc.'s Revenue Breakdown

As a clinical-stage company, Pulmatrix's revenue streams are subject to variability and heavily dependent on partnerships and developmental milestones.

Pulmatrix, Inc.'s Business Economics

Pulmatrix's business economics are characterized by significant investment in research and development, typical of a biotech company. Key aspects include:

• R&D Expenses: A substantial portion of operating expenses is dedicated to advancing its pipeline of drug candidates.
• Partnerships: Strategic alliances can provide financial support and expertise, influencing the company's economic stability.
• Clinical Trial Success: Positive clinical trial outcomes are critical for attracting investment and moving products toward commercialization.

More insights about the company can be found here: Mission Statement, Vision, & Core Values of Pulmatrix, Inc. (PULM).

Pulmatrix, Inc.'s Financial Performance

Pulmatrix's financial performance can be evaluated through the following lenses:

• Cash Runway: Monitoring cash reserves is vital, as it indicates the company's ability to fund ongoing operations and research activities.
• Operating Expenses: Analyzing operating expenses, particularly R&D, provides insights into investment in future growth.
• Net Losses: As a development-stage company, Pulmatrix typically experiences net losses as it invests heavily in its pipeline.

Pulmatrix, Inc. (PULM) Market Position & Future Outlook

Pulmatrix, Inc. is navigating a complex pharmaceutical landscape, striving to solidify its market position with innovative inhaled therapies and strategic collaborations. The company's future hinges on successful clinical trials, regulatory approvals, and effective commercialization strategies.

Competitive Landscape

Opportunities & Challenges

Industry Position

Pulmatrix, Inc. operates within the highly competitive pharmaceutical industry, specifically targeting the respiratory drug market. Its industry position can be characterized by:

• Niche Player: Focusing on innovative inhaled therapies using its proprietary iSPERSE™ technology.
• Development Stage: Primarily focused on clinical development with no products currently generating revenue.
• Partnership Dependent: Relies on strategic collaborations for funding, development, and commercialization.

To delve deeper into Pulmatrix, Inc.'s financial standing, explore: Breaking Down Pulmatrix, Inc. (PULM) Financial Health: Key Insights for Investors